Use of octreotide in the treatment of chylopericardium.

Abstract

Chylopericardium involves the pericardial effusion of chyle, which can be a primary (idiopathic) or secondary condition to injury or obstruction of the thoracic duct. We present a case of isolated chylopericardium that appeared after coronary artery bypass grafting in a 46-year-old woman. After failure of the usual conservative therapy for chylopericardium, ie, pericardial drainage and a low-fat, medium-chain triglyceride diet, her treatment was completed with octreotide, a long-acting somatostatin analog. Octreotide was used subcutaneously at a 3 × 100 μg daily dose for 2 weeks. The production of pericardial fluid decreased gradually, and had normalized by the end of treatment. No side effects were evident during therapy.

• Authors: Eszter Szabados, Kalman Toth, Emese Mezosi
• Journal: Heart & lung : the journal of critical care (Heart Lung) 2011 Nov-Dec Vol. 40 Issue 6 Pg. 574-5 ISSN: 1527-3288 [Electronic] United States
• PMID: 20561867 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents, Hormonal
• Octreotide

Topics

• Antineoplastic Agents, Hormonal (administration & dosage, therapeutic use)
• Coronary Artery Bypass (adverse effects)
• Female
• Humans
• Middle Aged
• Octreotide (administration & dosage, therapeutic use)
• Parenteral Nutrition, Total
• Pericardial Effusion (drug therapy, therapy)
• Treatment Failure